Zingiber cassumunar

Bonglai — bangle in Javanese and Indonesian usage, plai in Thailand — is a
rhizome of the massage tradition rather than the kitchen. Jamal and
colleagues' 2011 survey of Malay traditional practitioners records
Zingiber cassumunar among the frequently used species in postnatal care,
a practice built around heated rubs and pastes applied to strained muscle
[1]. The Han 2021 review documents parallel Thai and Indonesian traditional
use of the rhizome for muscle and joint complaints, sprains and swelling
[2]. The regional name-set is worth recording precisely: bonglai and
mengkulai are both current in Malay, and the accepted botanical synonym is
Zingiber montanum.

Two chemistries coexist in the rhizome. The essential oil is dominated by
monoterpenes — sabinene and terpinen-4-ol chief among them, characterised
in Indonesian material by Taroeno and colleagues in 1991 [3]. The
non-volatile fraction carries the phenylbutenoids, including compound D
((E)-4-(3,4-dimethoxyphenyl)but-3-en-1-ol) and DMPBD, inventoried in the
Han 2021 review [2]. DMPBD is the best-studied constituent in the
laboratory: Jeenapongsa and colleagues (2003) showed it dose-dependently
reduced experimentally induced ear oedema in rats, outperforming the
standard comparator compounds in that model [4]. DMPBD is also chemically
unstable, which raises real standardisation questions for any commercial
balm.

Two randomised trials anchor the grade. Niempoog and colleagues (2012) ran
a double-blind trial of Plygersic gel — a combination of plai and ginger
(Zingiber officinale) extracts — against 1% diclofenac gel in 100
patients with knee osteoarthritis over six weeks, and reported improved
KOOS scores with no significant difference between the gels [5]. Because
the gel combined two species, the trial cannot isolate bonglai's
contribution. Manimmanakorn and colleagues (2016) randomised 75 volunteers
to 14% or 7% plai cream or placebo, rubbed in after eccentric quadriceps
exercise, measuring soreness, strength, jump height and creatine kinase
over seven days [6] — a single-plant trial, in healthy volunteers rather
than patients.

Both trials are small, short, and from a single country, and no systematic
review meeting our inclusion criteria exists. Evidence for bonglai reaches
early clinical study; the grade remains B until independent replication
with a standardised, single-species preparation is published.

A systematic review published in 2017 gathered six studies covering 355
patients and concluded that a 14% plai cream is supported for muscle pain
and ankle sprain, while other proposed indications are not [8]. Later
randomised work has extended the range without settling it: a
placebo-controlled trial of a 15% balm in painful diabetic neuropathy
reported reduced pain at two and four weeks [9], and a trial in knee
osteoarthritis delivered the extract by phonophoresis [10]. Mechanistic
work continues on the phenylbutenoids that carry the activity [11], and
formulation studies address the skin permeation and stability of compound
D — a practical problem, given the instability noted above [12].

The systematic-review rung is therefore reached. What it found, however,
is limited and indication-specific evidence, which is why the grade sits
at B rather than higher.

Oral toxicity studies are reassuring: Koontongkaew and colleagues (2014)
found no treatment-related toxicity at a single 5,000 mg/kg dose in rats
and set a 270-day no-observed-adverse-effect level at 1,125 mg/kg/day [7].
Dermal safety data are thinner than the oral data. Patch-test before use;
do not apply to broken skin; the undiluted essential oil can irritate.
Data in pregnancy are limited — traditional postpartum use notwithstanding,
concentrated extracts deserve professional advice first.